Your SlideShare is downloading. ×
0
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Lean Startup Machine (Washington, DC): Salivation army
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Lean Startup Machine (Washington, DC): Salivation army

743

Published on

Presentation from the winning team, at the Lean Startup Machine event in Washington, D.C. 18-20 November 2011 …

Presentation from the winning team, at the Lean Startup Machine event in Washington, D.C. 18-20 November 2011

The team: Andrew Evans, Kevin May, Jenny Wong, ChanMi Park

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
743
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
0
Comments
0
Likes
1
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • \n
  • We thought 23andme audience are more likely to provide us with sample, that proved to be NOT true;\n\n
  • \n
  • 30% OF THE COST OF CLINICAL TRIAL, $2000 PER PERSON\n
  • \n
  • \n
  • We thought 23andme audience are more likely to provide us with sample, that proved to be NOT true;\n\n
  • \n\n
  • \n\n
  • \n
  • \n
  • \n
  • \n\n
  • \n
  • \n
  • \n
  • \n
  • \n
  • \n
  • \n
  • \n
  • Transcript

    • 1. WINNER OFWASHINGTON, D. C. 18 NOVEMBER 2011 Rob Shenk @ flickr
    • 2. WHAT IS THE PROBLEM?WE DON’T HAVE ENOUGH DATA TO ADVANCE MEDICINE
    • 3. PURE RESEARCH PROBLEM THE CURRENT DATABASE IS LIKE BINOCULARS TO AN ASTRONOMER WHEN WE NEED THE HUBBLE redrumblefish
    • 4. PHARMA / CRO PROBLEM WE’RE NOT LOOKING FOR A CLOWN FISH, WE’RE FINDING NEMO permasmirk
    • 5. “Your plans to host a database of over a million genomes linkereported and/or clinically anno d to self- tated phenotypes is an unprecresource for investigator s.  It w edented ould enable fast-paced pilot stfeasibility testing of initial projec udies or ts.  …  Consideration of paidthe data is well within grant aw access to ard mechanisms.” to reallyMichael E. Berens, Ph.D. "...incredibly exciting and has the potential ng withProfessor and Director, Cance r & Cell Biology Division change liv es… I’ll look forward to wor ki ogresses." d your team as your venture prTranslational Genomics Institu te (TGen) you an Sean Nolan Distinguished Engineer Microsoft Health Solutions medicine… "Pfizer is committed to suppor ting a future of precision ts comprised Platforms that suppor t the ab ility to generate integrated datase value… The of clinical and genetic data bring the potential for significant as well no vel clinical and genetic data assets potential for such tools to build lopment." as impact education of provider s and patients merits further deve Craig Lipset "This is definitely something that Q uintiles would be interested Head of Clinical Innovation in… With us being able to link mor e and more phenotypical Pfizer characteristics to genotype data, th is database that Andy is talking about will be extremely valuable fo r both potential clinical trial design and planning as well as exec ution of CER-type studies thatINDUSTRY are becoming more and more popu lar on the payer side." John Jones Practice Lead, IT Strategy & Implem entationINTERESTS Quintiles
    • 6. LET THE GAMES BEGIN! 300+ MILLION ACTIVE GAMERS LACK OF CUSTOMIZATION VIRTUAL GOODS MARKET
    • 7. OUR SOLUTIONWilling to solve genome problems through gamification Incentivize participants using virtual currency Pharmaceutical companies are willing to pay for data
    • 8. HYPOTHESES WE CAN STEAL USERS FROM 23ANDMETHE GAME OFFERING IS COMPELLING ENOUGH TO GIVE AWAY THEIR DNA PEOPLE WANT TO PERSONALIZE THEIR GAMING EXPERIENCE
    • 9. WE PUT OUT A SURVEY
    • 10. rockcreek TAKING IT TO THE STREETS Michael6076thogeo Stephen Bess owash
    • 11. THE PIVOT Do you want toplay a video game to solve genetic Hey you want to give problems? up sensitive, personal information to solve genetic diseases in the world? mrlerone
    • 12. HYPOTHESES 2.0 ALTRUISM IS A BETTER INCENTIVEPEOPLE WOULD PART WITH THEIR DNA TO BE A PART OF SOMETHING BIGGER
    • 13. OUR PROPS
    • 14. WE ARE THE SALIVATION ARMYYou spit into a tubeWe read your DNAWe combine it into an ArmyTogether with our industry partners, we crush diseaseWe report back to you regularly from the front lines
    • 15. SHOWING OUR IDEA TO THE PUBLIC
    • 16. TALKING TO PEOPLE, TAKING SALIVA SAMPLES
    • 17. FACTS
    • 18. THE MVP
    • 19. THE POTENTIAL $42 BN MARKET100% ROI PER TRIAL PARTICIPANT
    • 20. THE TEAMKEVIN MAY, ANDREW EVANS, CHANMI PARK, JENNY WONG

    ×